source
- FDA rejects Summit’s ivonescimab, citing China‑centric data and missed survival benefitThe FDA sent Summit Therapeutics a complete response letter on Nov 13, rejecting its PD‑1×VEGF bispecific antibody ivonescimab. Reviewers said the pivotal HARMONi trial was dominated by patients f…
- FDA issues complete response letter, rejecting Summit Therapeutics' ivonescimab for EGFR-mutated lung cancerThe U.S. Food and Drug Administration sent a complete response letter to Summit Therapeutics, declining to approve its bispecific antibody ivonescimab for patients with previously treated EGFR‑muta…